Patients With Atopic Dermatitis Treated With Upadacitinib: Factors Related to Achieving Minimal Disease Activity
Dermatitis® · 01.11.2026 · 37 (6) · 975-981
DOI: 10.1089/derm.2024.0553 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Dermatitis®, online erschienen am 21.05.2025. Verfasst von Andrea I Rodriguez-Sanna und 6 weiteren Autor:innen. Beteiligte Einrichtung: From the, Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a chronic skin condition that may require systemic treatments like traditional immunosuppressants or advanced therapies such as upadacitinib, a JAK1-selective inhibitor. Minimal disease activity (MDA), a novel concept combining patient–clinician decision-making, offers a comprehensive measure of disease management, yet its use in real-world drug efficacy studies is limited.
Objective
This study aimed to assess the proportion of patients achieving MDA based on pruritus (MDAp) after 16 and 52 weeks of upadacitinib treatment and to explore factors associated with MDA achievement.
Methods
A prospective observational study was designed, including patients with moderate-to-severe AD starting treatment with upadacitinib for the first time. MDAp was defined as ≥90% improvement in the Eczema Area Severity Index and Worst Pruritus Numerical Rating Scale score ≤1.
Results
Fifty-three patients participated; mean age was 33.53 years (standard deviation 15.40), and 58.5% were women. MDAp was achieved by 62.3% of patients at week 16 and 46.2% at week 52. Patients achieving MDAp at week 16 were older, had shorter disease duration, and had less prior systemic corticosteroid use.
Conclusions
Upadacitinib demonstrated efficacy in achieving MDAp in moderate-to-severe AD. Clinical and therapeutic factors identified in this study could help predict treatment success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the, Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
- Pharmacy Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
- Dermatology Department, Hospital Universitario de Jaén, Jaén, Spain.
- Instituto de Investigación Biosanitaria ibs GRANADA, Granada, Spain.
- Dermatology Department, School of Medicine, University of Granada, Granada, Spain.
ORCID-Profile: Andrea I Rodriguez-Sanna, Trinidad Montero-Vilchez
Zitieren
APA
Rodriguez-Sanna, A. I., Montero-Vilchez, C., Moreno-Suarez, F. G., Garrido-Colmenero, C., Aceituno-Madera, P., Arias-Santiago, S., & Montero-Vilchez, T. (2026). Patients With Atopic Dermatitis Treated With Upadacitinib: Factors Related to Achieving Minimal Disease Activity. Dermatitis®, 37(6), 975-981. https://doi.org/10.1089/derm.2024.0553
Vancouver
Rodriguez-Sanna AI, Montero-Vilchez C, Moreno-Suarez FG, Garrido-Colmenero C, Aceituno-Madera P, Arias-Santiago S, et al. Patients With Atopic Dermatitis Treated With Upadacitinib: Factors Related to Achieving Minimal Disease Activity. Dermatitis®. 2026;37(6):975-981. doi:10.1089/derm.2024.0553
BibTeX
@article{RodriguezSanna2026,
author = {Rodriguez-Sanna, Andrea I and Montero-Vilchez, Carolina and Moreno-Suarez, Fatima G and Garrido-Colmenero, Cristina and Aceituno-Madera, Pedro and Arias-Santiago, Salvador and Montero-Vilchez, Trinidad},
title = {Patients With Atopic Dermatitis Treated With Upadacitinib: Factors Related to Achieving Minimal Disease Activity},
journal = {Dermatitis®},
year = {2026},
volume = {37},
number = {6},
pages = {975--981},
doi = {10.1089/derm.2024.0553}
}
EUVIMED